MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3760/cma.j.issn.0253-2727.2015.08.005

Медицинская библиотека · Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015

[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].

Jiang Qian, Zhao Donglu, Jin Jie, Wu Depei, Meng Fanyi, Hu Jianda, Liu Bingcheng, DU Xin, Liu Ting, Li Yan, Hou Ming, Han Xiaopin, Shen Zhixiang, Ma Jun

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate the early hematologic, cytogenetic and molecular responses in newly diagnosed patients with chronic myelogenous leukemia in chronic phase(CML-CP)and initially treated with a generic imatinib(Xinwei), manufactured by Jiansu Hansoh Pharmaceutical Group Co., Ltd.

METHODS

107 newly diagnosed patients of CML-CP, whose ages were above 18- year- old and who had never received any tyrosine kinase inhibitor(TKI)were treated with Xinwei 400 mg QD. The hematologic, cytogenetic and molecular responses were assessed at 3- and 6-month, and adverse effects were evaluated throughout the study.

RESULTS

107 patients were treated with Xinwei for at least 3 months, 54 of them were treated for 6 months or more. At 3- month, the complete hematologic responses(CHR)rate were 98.1%(105/107); 47/57(82.5%) patients achieved major cytogenetic response(MCyR), and 20/57 (35.1%) patients complete cytogenetic response(CCyR); BCR- ABLIS was ≤10% in 77/106 patients (72.6%), 11 of them(10.4%)achieved major molecular response(MMR, BCR-ABLIS was ≤0.1%). At 6-month, the CHR rate was 100%(54/54); 28/39 patients(71.8%)achieved CCyR; BCR-ABLIS was ≤1% in 37/54 patients (68.5% ), 18 of them (33.3% ) achieved MMR. The grade Ⅲ leukopenia, thrombocytopenia and anemia rates were 19.5%, 23.0% and 13.8%, respectively. No grade Ⅳ hematologic toxicity occurred. The common non- hematologic toxicities were edema(74.7%), nausea(48.3%), bone pain(42.5%), rash(36.8%), diarrhea(34.5%), fever(23.0%), cramp(11.5%)and impaired liver function (3.4%). No patient experienced grade Ⅳ non- hematologic toxicity. No adverse effects related death occurred.

CONCLUSION

Our results revealed the excellent early haematology, cytogenetic and molecular responses and safety of Xinwei in treating patients with CML-CP.

Для цитирования: Jiang Qian, Zhao Donglu, Jin Jie, Wu Depei, Meng Fanyi, Hu Jianda, Liu Bingcheng, DU Xin, Liu Ting, Li Yan, Hou Ming, Han Xiaopin, Shen Zhixiang, Ma Jun. [A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2015. DOI: 10.3760/cma.j.issn.0253-2727.2015.08.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.